Table 4. Effect of CD4 cell count and HIV viral load on the relationship of KIR2DL3 and KIR2DL2/KIR2DL2 with PM in HIV-1 infected women, outcome placental malaria (PM) status.
| Parameter, level | No. of women | PM (%) | Adjusted OR | Pa |
| (No. with Gene) | (95%CI) | |||
| KIR2DL3 | Present vs. Absent | |||
| CD4 cell count, cells/µl | ||||
| <350 | 80 (69) | 21.3 | 0.70 (0.16–3.03) | 0.63 |
| ≥350 | 346 (296) | 22.0 | 0.35 (0.18–0.67) | 0.002** |
| HIV-1 load, copies/ml | ||||
| <10,000 | 309 (267) | 19.4 | 0.44 (0.21–0.93) | 0.031* |
| ≥10,000 | 69 (57) | 27.5 | 1.20 (0.28–5.24) | 0.80 |
| KIR2DL2/KIR2DL2 | 2DL2/2DL2 vs. 2DL3/2DL3 | |||
| CD4 cell count, cells/µl | ||||
| <350 | 80 (11) | 21.3 | 1.13 (0.23–5.44) | 0.88 |
| ≥350 | 345(49) | 22.0 | 2.82 (1.40–5.68) | 0.004** |
| HIV-1 load, copies/ml | ||||
| <10,000 | 309 (42) | 19.4 | 2.10 (0.95–4.68) | 0.069 |
| ≥10,000 | 69 (12) | 27.5 | 1.13 (0.24–5.40) | 0.88 |
Note: PM = Placental malaria. OR = Odds ratio, CI = Confidence interval. Pa derived from multivariable logistic regression, controlling for gravidity, anti-malarial use during third trimester, and malaria transmission season. Similar to previous analysis the reference group was selected based on the group with highest frequency for the significant gene pair and based on the absence for significant individual gene.
False Discovery Rate (FDR) was used to correct P-values.
‘*’
signifies uncorrected P-value that is <0.05 but is non-significant after correction.
‘**’
signifies uncorrected P-value that is significant after correction.